Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465173 | 1.00 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL1387661 | 1.00 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL8380396 | 0.92 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL8239487 | 0.92 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL8239482 | 0.92 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL8380393 | 0.92 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL8200621 | 0.92 | SLC10A2 (0.52) | SLC10A2 | |
| SCHEMBL8194080 | 0.91 | SLC10A2 (0.42) | SLC10A2 | |
| SCHEMBL8223063 | 0.91 | SLC10A2 (0.47) | SLC10A2 | |
| SCHEMBL22347035 | 0.91 | SLC10A2 (0.47) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-H10504035-A | — | — | 1998-04-14 | — | — | JP | claimed |
| EP-0775126-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-05-28 | — | — | EP | claimed |
| WO-1996005188-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| EP-2968262-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968230-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015065983-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014144485-A9 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014144650-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144485-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2770990-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2771003-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013063512-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS, INC (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2575821-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2013020108-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011150286-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS,INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-0775126-B1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | WELLCOME FOUND (GB) | 2002-10-30 | — | — | EP | disclosed |
| EP-1203769-A1 | Hypolipidemic 1,4-benzothiazepine derivative | THE WELLCOME FOUNDATION LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| US-5910494-A | NOVEL COMPOUNDS THAT REDUCE THE ABSORPTION OF BILE ACIDS FROM THE INTESTINE; FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS, SUCH AS ATHEROSCLEROSIS | GLAXO WELLCOME INC. (US) | 1999-06-08 | — | — | US | disclosed |
| EP-0775126-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005188-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |